請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34614完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 蘇慧敏 | |
| dc.contributor.author | Pao-Yuan Wang | en |
| dc.contributor.author | 王寶源 | zh_TW |
| dc.date.accessioned | 2021-06-13T06:18:22Z | - |
| dc.date.available | 2007-02-09 | |
| dc.date.copyright | 2006-02-09 | |
| dc.date.issued | 2006 | |
| dc.date.submitted | 2006-01-26 | |
| dc.identifier.citation | AHMAD A, MORIGUCHI T & SALEM N. (2002). Decrease in neuron size in docosahexaenoic acid-deficient brain. Pediatr Neurol 26, 210-218.
AKBAR M & KIM HY. (2002). Protective effects of docosahexaenoic acid in staurosporine-induced apoptosis: involvement of phosphatidylinositol-3 kinase pathway. J Neurochem 82, 655-665. AKSENOV MY, AKSENOVA MV, BUTTERFIELD DA, GEDDES JW & MARKESBERY WR. (2001). Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383. AKSENOVA MV, AKSENOV MY, PAYNE RM, TROJANOWSKI JQ, SCHMIDT ML, CARNEY JM, BUTTERFIELD DA & MARKESBERY WR. (1999). Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement Geriatr Cogn Disord 10, 158-165. ALBERTS B, JOHNSON A, LEWIS J, RAFF M, ROBERTS K & WALTER P. (2002). molecular biology of the cell. ANDORFER C, KRESS Y, ESPINOZA M, DE SILVA R, TUCKER KL, BARDE YA, DUFF K & DAVIES P. (2003). Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem 86, 582-590. ANNAERT W & DE STROOPER B. (2002). A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 18, 25-51. AVILA J, LUCAS JJ, PEREZ M & HERNANDEZ F. (2004). Role of tau protein in both physiological and pathological conditions. Physiol Rev 84, 361-384. BAAS PW & QIANG L. (2005). Neuronal microtubules: when the MAP is the roadblock. Trends Cell Biol 15, 183-187. BAZAN NG. (2005). Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 15, 159-166. BEAR MF, CONNORS BW & PARADISO MA. (2001). Neuroscience. BECKER WM, KLEINSMITH LJ & HARDIN J. (2000). The world of the cell. BECKER WM, KLEINSMITH LJ & HARDIN J. (2000). The world of the dell. BOSSY-WETZEL E, SCHWARZENBACHER R & LIPTON SA. (2004). Molecular pathways to neurodegeneration. Nat Med 10 Suppl, S2-9. BRAND A, GIL S & YAVIN E. (2000). N-methyl bases of ethanolamine prevent apoptotic cell death induced by oxidative stress in cells of oligodendroglia origin. J Neurochem 74, 1596-1604. BUTTERFIELD DA. (2002). Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36, 1307-1313. BUTTERFIELD DA, CASTEGNA A, LAUDERBACK CM & DRAKE J. (2002). Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23, 655-664. BUTTERFIELD DA, GRIFFIN S, MUNCH G & PASINETTI GM. (2002). Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis 4, 193-201. BUTTERFIELD DA & LAUDERBACK CM. (2002). Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32, 1050-1060. CALON F, LIM GP, YANG F, MORIHARA T, TETER B, UBEDA O, ROSTAING P, TRILLER A, SALEM N, JR., ASHE KH, FRAUTSCHY SA & COLE GM. (2004). Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43, 633-645. CHANG KA & SUH YH. (2005). Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. J Pharmacol Sci 97, 461-471. CHO JH & JOHNSON GV. (2004). Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem 279, 54716-54723. CLARK CM & KARLAWISH JH. (2003). Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 138, 400-410. COOPER EC & LOWWENSTEIN DH. (2002). Hippocampus. Encyclopedia of life sciences. CRAWLEY JN, GERFEN CR, ROGAWSKI MA, SIBLEY DR, SKOLNICK P & WRAY S. (2005). Current Protocols in Neuroscience. CROSBY AH. (2003). Disruption of cellular transport: a common cause of neurodegeneration? Lancet Neurol 2, 311-316. DAS UN. (2003). Long-chain polyunsaturated fatty acids in memory formation and consolidation: further evidence and discussion. Nutrition 19, 988-993. DAS UN & FAMS. (2003). Long-chain polyunsaturated fatty acids in the growth and development of the brain and memory. Nutrition 19, 62-65. DAWSON HN, FERREIRA A, EYSTER MV, GHOSHAL N, BINDER LI & VITEK MP. (2001). Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114, 1179-1187. DICKSON DW. (2004). Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? J Clin Invest 114, 23-27. DINELEY KT, WESTERMAN M, BUI D, BELL K, ASHE KH & SWEATT JD. (2001). Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21, 4125-4133. DOUGHERTY JJ, WU J & NICHOLS RA. (2003). Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex. J Neurosci 23, 6740-6747. ECKERT A, KEIL U, MARQUES CA, BONERT A, FREY C, SCHUSSEL K & MULLER WE. (2003). Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 66, 1627-1634. ERIKSSON PS, PERFILIEVA E, BJORK-ERIKSSON T, ALBORN AM, NORDBORG C, PETERSON DA & GAGE FH. (1998). Neurogenesis in the adult human hippocampus. Nat Med 4, 1313-1317. FAVRELIERE S, PERAULT MC, HUGUET F, DE JAVEL D, BERTRAND N, PIRIOU A & DURAND G. (2003). DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. Neurobiol Aging 24, 233-243. FEINSTEIN SC & WILSON L. (2005). Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta 1739, 268-279. FIFRE A, SPONNE I, KOZIEL V, KRIEM B, YEN-POTIN FT, BIHAIN BB, OLIVIER JL, OSTER T & PILLOT T. (2005). Microtubule-associated proteins MAP1A, MAP1B and MAP2 proteolysis during soluble amyloid-beta peptide induced neuronal apoptosis: Synergistic involvement of calpain and caspase-3. J Biol Chem. FINK JK, JONES SM, ESPOSITO C & WILKOWSKI J. (1996). Human microtubule-associated protein 1a (MAP1A) gene: genomic organization, cDNA sequence, and developmental- and tissue-specific expression. Genomics 35, 577-585. FLEITH M & CLANDININ MT. (2005). Dietary PUFA for preterm and term infants: review of clinical studies. Crit Rev Food Sci Nutr 45, 205-229. FLODEN AM, LI S & COMBS CK. (2005). Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25, 2566-2575. FLORENT S, MALAPLATE-ARMAND C, YOUSSEF I, KRIEM B, KOZIEL V, ESCANYE MC, FIFRE A, SPONNE I, LEININGER-MULLER B, OLIVIER JL, PILLOT T & OSTER T. (2005). Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J Neurochem. FRIEDLAND RP. (2002). Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease. Ann N Y Acad Sci 977, 387-390. FUKUMOTO H, ROSENE DL, MOSS MB, RAJU S, HYMAN BT & IRIZARRY MC. (2004). Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 164, 719-725. GAMOH S, HASHIMOTO M, SUGIOKA K, SHAHDAT HOSSAIN M, HATA N, MISAWA Y & MASUMURA S. (1999). Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 93, 237-241. GARCIA ML & CLEVELAND DW. (2001). Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol 13, 41-48. GESCHWIND DH. (2003). Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg? Neuron 40, 457-460. GONZALEZ-BILLAULT C, JIMENEZ-MATEOS EM, CACERES A, DIAZ-NIDO J, WANDOSELL F & AVILA J. (2004). Microtubule-associated protein 1B function during normal development, regeneration, and pathological conditions in the nervous system. J Neurobiol 58, 48-59. GOTZ J, SCHILD A, HOERNDLI F & PENNANEN L. (2004). Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci 22, 453-465. GREENBERG SM, KOO EH, SELKOE DJ, QIU WQ & KOSIK KS. (1994). Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci U S A 91, 7104-7108. GUNGABISSOON RA & BAMBURG JR. (2003). Regulation of growth cone actin dynamics by ADF/cofilin. J Histochem Cytochem 51, 411-420. HAASS C. (2004). Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. Embo J 23, 483-488. HAMDANE M, DELOBEL P, SAMBO AV, SMET C, BEGARD S, VIOLLEAU A, LANDRIEU I, DELACOURTE A, LIPPENS G, FLAMENT S & BUEE L. (2003). Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis? Biochem Pharmacol 66, 1619-1625. HARDY J & SELKOE DJ. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. HASHIMOTO M, HOSSAIN S, SHIMADA T, SUGIOKA K, YAMASAKI H, FUJII Y, ISHIBASHI Y, OKA J & SHIDO O. (2002). Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81, 1084-1091. HASHIMOTO M, TANABE Y, FUJII Y, KIKUTA T, SHIBATA H & SHIDO O. (2005). Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 135, 549-555. HAUGHEY NJ, NATH A, CHAN SL, BORCHARD AC, RAO MS & MATTSON MP. (2002). Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem 83, 1509-1524. HELMUTH L. (2001). Detangling Alzheimer's disease. Sci Aging Knowledge Environ 2001, oa2. HENSLEY K, HALL N, SUBRAMANIAM R, COLE P, HARRIS M, AKSENOV M, AKSENOVA M, GABBITA SP, WU JF, CARNEY JM & ET AL. (1995). Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65, 2146-2156. HEREDIA L, LIN R, VIGO FS, KEDIKIAN G, BUSCIGLIO J & LORENZO A. (2004). Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid beta precursor protein. Neurobiol Dis 16, 617-629. HOLSINGER RM, MCLEAN CA, BEYREUTHER K, MASTERS CL & EVIN G. (2002). Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol 51, 783-786. HORROCKS LA & YEO YK. (1999). Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 40, 211-225. HOYER S. (2004). Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490, 115-125. HUSE JT, LIU K, PIJAK DS, CARLIN D, LEE VM & DOMS RW. (2002). Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J Biol Chem 277, 16278-16284. JANMEY PA & LINDBERG U. (2004). Cytoskeletal regulation: rich in lipids. Nat Rev Mol Cell Biol 5, 658-666. JOHNSON GV & STOOTHOFF WH. (2004). Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117, 5721-5729. KAMBOH MI. (2004). Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet 68, 381-404. KAMENETZ F, TOMITA T, HSIEH H, SEABROOK G, BORCHELT D, IWATSUBO T, SISODIA S & MALINOW R. (2003). APP processing and synaptic function. Neuron 37, 925-937. KECK S, NITSCH R, GRUNE T & ULLRICH O. (2003). Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 85, 115-122. KHALILOV I, ESCLAPEZ M, MEDINA I, AGGOUN D, LAMSA K, LEINEKUGEL X, KHAZIPOV R & BEN-ARI Y. (1997). A novel in vitro preparation: the intact hippocampal formation. Neuron 19, 743-749. KIM HY, AKBAR M, LAU A & EDSALL L. (2000). Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 275, 35215-35223. KIMBERLY WT & WOLFE MS. (2003). Identity and function of gamma-secretase. J Neurosci Res 74, 353-360. KORNACK DR & RAKIC P. (1999). Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Proc Natl Acad Sci U S A 96, 5768-5773. KOWALSKA A. (2004). Genetic basis of neurodegeneration in familial Alzheimer's disease. Pol J Pharmacol 56, 171-178. LAURIN D, VERREAULT R, LINDSAY J, DEWAILLY E & HOLUB BJ. (2003). Omega-3 fatty acids and risk of cognitive impairment and dementia. J Alzheimers Dis 5, 315-322. LAURITZEN I, BLONDEAU N, HEURTEAUX C, WIDMANN C, ROMEY G & LAZDUNSKI M. (2000). Polyunsaturated fatty acids are potent neuroprotectors. Embo J 19, 1784-1793. LEVINE H, 3RD. (2004). The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide. J Alzheimers Dis 6, 303-314. LI R, LINDHOLM K, YANG LB, YUE X, CITRON M, YAN R, BEACH T, SUE L, SABBAGH M, CAI H, WONG P, PRICE D & SHEN Y. (2004). Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A 101, 3632-3637. LIM GP, CALON F, MORIHARA T, YANG F, TETER B, UBEDA O, SALEM N, JR., FRAUTSCHY SA & COLE GM. (2005). A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25, 3032-3040. LIU SJ, ZHANG AH, LI HL, WANG Q, DENG HM, NETZER WJ, XU H & WANG JZ. (2003). Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87, 1333-1344. LOPEZ SALON M, PASQUINI L, BESIO MORENO M, PASQUINI JM & SOTO E. (2003). Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 180, 131-143. LU DC, SORIANO S, BREDESEN DE & KOO EH. (2003). Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity. J Neurochem 87, 733-741. MACIVER SK. (2001). Polymerization dynamics of cytoskeletal filaments. Encyclopediaof life sciences. MACRAE TH. (1997). Tubulin post-translational modifications--enzymes and their mechanisms of action. Eur J Biochem 244, 265-278. MALONEY MT, MINAMIDE LS, KINLEY AW, BOYLE JA & BAMBURG JR. (2005). Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease. J Neurosci 25, 11313-11321. MANDELKOW E. (1999). Alzheimer's disease. The tangled tale of tau. Nature 402, 588-589. MASKERY S & SHINBROT T. (2005). Deterministic and stochastic elements of axonal guidance. Annu Rev Biomed Eng 7, 187-221. MATTSON MP. (2004). Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. MATTSON MP, PARTIN J & BEGLEY JG. (1998). Amyloid beta-peptide induces apoptosis-related events in synapses and dendrites. Brain Res 807, 167-176. MATUS A, BRINKHAUS H & WAGNER U. (2000). Actin dynamics in dendritic spines: a form of regulated plasticity at excitatory synapses. Hippocampus 10, 555-560. MCCANN JC & AMES BN. (2005). Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 82, 281-295. MCGAHON BM, MARTIN DS, HORROBIN DF & LYNCH MA. (1999). Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 94, 305-314. MICHAELIS ML. (2003). Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther 304, 897-904. MICHIKAWA M, GONG JS, FAN QW, SAWAMURA N & YANAGISAWA K. (2001). A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J Neurosci 21, 7226-7235. MILNER B. (1954). Intellectual function of the temporal lobes. Psychol Bull 51, 42-62. MINAMI M, KIMURA S, ENDO T, HAMAUE N, HIRAFUJI M, TOGASHI H, MATSUMOTO M, YOSHIOKA M, SAITO H, WATANABE S, KOBAYASHI T & OKUYAMA H. (1997). Dietary docosahexaenoic acid increases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 58, 1123-1129. MIRNIKJOO B, BROWN SE, KIM HF, MARANGELL LB, SWEATT JD & WEEBER EJ. (2001). Protein kinase inhibition by omega-3 fatty acids. J Biol Chem 276, 10888-10896. MONTINE TJ & MORROW JD. (2005). Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol 166, 1283-1289. MUDHER A & LOVESTONE S. (2002). Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 25, 22-26. MULLER U & KINS S. (2002). APP on the move. Trends Mol Med 8, 152-155. MUSKIET FA, FOKKEMA MR, SCHAAFSMA A, BOERSMA ER & CRAWFORD MA. (2004). Is docosahexaenoic acid (DHA) essential? Lessons from DHA status regulation, our ancient diet, epidemiology and randomized controlled trials. J Nutr 134, 183-186. NAZAREVSKAIA GD & REZNIKOV K. (1984). [Spatial localization of proliferating and dying cells in the developing hippocampus in the mouse]. Arkh Anat Gistol Embriol 87, 31-37. NICHOLSON-DYKSTRA S, HIGGS HN & HARRIS ES. (2005). Actin dynamics: growth from dendritic branches. Curr Biol 15, R346-357. NOWOTNY P, KWON JM & GOATE AM. (2001). Alzheimer'a disease. Encyclopedia of life sciences. PARENT JM, YU TW, LEIBOWITZ RT, GESCHWIND DH, SLOVITER RS & LOWENSTEIN DH. (1997). Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J Neurosci 17, 3727-3738. PIPERNO G, LEDIZET M & CHANG XJ. (1987). Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 104, 289-302. QIU WQ, WALSH DM, YE Z, VEKRELLIS K, ZHANG J, PODLISNY MB, ROSNER MR, SAFAVI A, HERSH LB & SELKOE DJ. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273, 32730-32738. RACCHI M & GOVONI S. (2003). The pharmacology of amyloid precursor protein processing. Exp Gerontol 38, 145-157. RAMETTI A, ESCLAIRE F, YARDIN C & TERRO F. (2004). Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J Biol Chem 279, 54518-54528. RAPOPORT M, DAWSON HN, BINDER LI, VITEK MP & FERREIRA A. (2002). Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99, 6364-6369. ROGERS J, STROHMEYER R, KOVELOWSKI CJ & LI R. (2002). Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 40, 260-269. ROY NS, WANG S, JIANG L, KANG J, BENRAISS A, HARRISON-RESTELLI C, FRASER RA, COULDWELL WT, KAWAGUCHI A, OKANO H, NEDERGAARD M & GOLDMAN SA. (2000). In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat Med 6, 271-277. SANCHEZ C, DIAZ-NIDO J & AVILA J. (2000). Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Prog Neurobiol 61, 133-168. SCHULZE E, ASAI DJ, BULINSKI JC & KIRSCHNER M. (1987). Posttranslational modification and microtubule stability. J Cell Biol 105, 2167-2177. SCHULZE E & KIRSCHNER M. (1987). Dynamic and stable populations of microtubules in cells. J Cell Biol 104, 277-288. SELKOE DJ, PODLISNY MB, JOACHIM CL, VICKERS EA, LEE G, FRITZ LC & OLTERSDORF T. (1988). Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci U S A 85, 7341-7345. SISODIA SS & ST GEORGE-HYSLOP PH. (2002). gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3, 281-290. SMALL DH, MOK SS & BORNSTEIN JC. (2001). Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2, 595-598. SMITH CD, CARNEY JM, STARKE-REED PE, OLIVER CN, STADTMAN ER, FLOYD RA & MARKESBERY WR. (1991). Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 88, 10540-10543. SODERBERG M, EDLUND C, KRISTENSSON K & DALLNER G. (1991). Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26, 421-425. SORIANO E, COBAS A & FAIREN A. (1986). Asynchronism in the neurogenesis of GABAergic and non-GABAergic neurons in the mouse hippocampus. Brain Res 395, 88-92. SPONNE I, FIFRE A, DROUET B, KLEIN C, KOZIEL V, PINCON-RAYMOND M, OLIVIER JL, CHAMBAZ J & PILLOT T. (2003). Apoptotic neuronal cell death induced by the non-fibrillar amyloid-beta peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J Biol Chem 278, 3437-3445. SU HM, KESWICK LA & BRENNA JT. (1996). Increasing dietary linoleic acid in young rats increases and then decreases docosahexaenoic acid in retina but not in brain. Lipids 31, 1289-1298. TAKAHASHI RH, ALMEIDA CG, KEARNEY PF, YU F, LIN MT, MILNER TA & GOURAS GK. (2004). Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24, 3592-3599. TAKAHASHI RH, MILNER TA, LI F, NAM EE, EDGAR MA, YAMAGUCHI H, BEAL MF, XU H, GREENGARD P & GOURAS GK. (2002). Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161, 1869-1879. TAKAHASHI RH, NAM EE, EDGAR M & GOURAS GK. (2002). Alzheimer beta-amyloid peptides: normal and abnormal localization. Histol Histopathol 17, 239-246. TANZI RE & BERTRAM L. (2005). Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555. THEUNS J & VAN BROECKHOVEN C. (2000). Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. Hum Mol Genet 9, 2383-2394. TORREILLES F & TOUCHON J. (2002). Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease. Prog Neurobiol 66, 191-203. TULLY AM, ROCHE HM, DOYLE R, FALLON C, BRUCE I, LAWLOR B, COAKLEY D & GIBNEY MJ. (2003). Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89, 483-489. TURNER PR, O'CONNOR K, TATE WP & ABRAHAM WC. (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70, 1-32. VALIRON O, CAUDRON N & JOB D. (2001). Microtubule dynamics. Cell Mol Life Sci 58, 2069-2084. VERDILE G, FULLER S, ATWOOD CS, LAWS SM, GANDY SE & MARTINS RN. (2004). The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 50, 397-409. VITOLO OV, SANT'ANGELO A, COSTANZO V, BATTAGLIA F, ARANCIO O & SHELANSKI M. (2002). Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 99, 13217-13221. WALSH DM, KLYUBIN I, FADEEVA JV, CULLEN WK, ANWYL R, WOLFE MS, ROWAN MJ & SELKOE DJ. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539. WALSH DM, KLYUBIN I, FADEEVA JV, ROWAN MJ & SELKOE DJ. (2002). Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 30, 552-557. WANG X, ZHAO X, MAO ZY, WANG XM & LIU ZL. (2003). Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. Neuroreport 14, 2457-2461. WEHRLE-HALLER B & IMHOF BA. (2003). Actin, microtubules and focal adhesion dynamics during cell migration. Int J Biochem Cell Biol 35, 39-50. WIRTHS O, MULTHAUP G & BAYER TA. (2004). A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade. J Neurochem 91, 513-520. YANG F, SUN X, BEECH W, TETER B, WU S, SIGEL J, VINTERS HV, FRAUTSCHY SA & COLE GM. (1998). Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease. Am J Pathol 152, 379-389. YANG LB, LINDHOLM K, YAN R, CITRON M, XIA W, YANG XL, BEACH T, SUE L, WONG P, PRICE D, LI R & SHEN Y. (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 9, 3-4. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34614 | - |
| dc.description.abstract | 本論文在探討二十二碳六烯酸(Docosahexaenoic acid,DHA,22:6ω3)對阿茲海默氏病(Alzheimer’s disease, AD)可能的預防機轉。AD是一種神經退化性疾病，好發於老年人，在患者腦部有老年斑塊(senile plaque)與神經纖維纏結(neurofibrillary tangle)等特徵。老年斑塊是由類澱粉蛋白(β-amyloid peptide, Aβ)在神經細胞外堆積而成，而神經纖維纏結是由過度磷酸化的Tau蛋白在神經細胞內堆積而成，並造成細胞內微小管(microtubule)斷裂、動態(dynamics)降低的現象。DHA是神經細胞膜上最重要的多不飽和脂肪酸，對大腦的發育及正常功能的維持極為重要。
利用懷孕期第十八天胎鼠的海馬回做初級細胞培養，在培養液中添加0~50uM DHA，發現：（1）以細胞型態完整性分析，當添加10μM DHA時細胞有最高存活率。當添加25μM DHA時最能抵抗Aβ42的毒性並有較高細胞存活率。（2）以氣相層析儀(Gas chromatograph,GC)分析，發現DHA添加量越多，細胞內DHA含量也越多，呈現濃度依賴效應(dose-dependent effect)，當添加至25μM時，神經細胞內DHA含量達到高原期(plateau)。（3）以西方點墨法(Western blot)分析，發現添加DHA的海馬回細胞其代表微小管動態上升的tyrosinated tubulin蛋白質表現在添加DHA 5μM時上升61 %，代表動態下降的acetylated tubulin蛋白質表現在DHA 25μM上升9 %，表示DHA可調控微小管動態，其變化正與添加DHA存活率趨勢相符。此外，actin蛋白質表現在添加25μM DHA時下降37 %。 綜合以上結果，我們發現DHA可以經由培養液併入海馬回神經細胞，並增加微小管動態以抵抗類澱粉蛋白引起的的神經毒性，提高神經細胞的存活率。證明DHA對預防阿茲海默氏病的確有相當的效果。 | zh_TW |
| dc.description.abstract | Alzheimer’s disease (AD) is a progressing neurodegenerative disease characterized by dementia to a degree that it infers with person’s ability and function. The aim of the study is to understand the mechanism of docosahexaenoic acid (DHA, 22:6ω3) on the progression of AD by conducting studies in primary hippocampal cells supplemented with 0~50 uM DHA. We hypothesized that increased DHA level in membrane structure of hippocampal neuron would build up a barrier to against neurotoxicity induced by fibrillar amyloid b peptide (Ab42), and increased microtubules dynamics.
It was found that: （1）The optimal concentration of DHA for the survival of cultiured primary hippocampal cells was 10μM. （2）The DHA supplemented to the medium did increase the DHA level in hippocampal cells as a dose-dependent level. （3）The increased DHA level in hippocampal cells did against neurotoxicity induced by fibrillar Ab42 to increase its cell viability. （4）The 5uM but not 25uM DHA supplemented to medium did increase 61% tyrosinated tubulin expression, a maker of dynamic microtubules, compare with controls. （5）The 25uM but not 5uM DHA supplemented to medium did upregulate 9% acetylated tubulin expression, a maker of stabilized microtubules, compared with controls. （6）The 25uM but not 5uM DHA supplemented to medium did downregulate 37%β-actin compared with controls. We concluded that the supplemented DHA can be incorporated into the hippocampal cells to increase its survival, did against Aβ42 induced neurotoxicity and regulate microtubule dynamics, suggesting DHA is a potential supplement for AD prevention. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T06:18:22Z (GMT). No. of bitstreams: 1 ntu-95-R92441001-1.pdf: 2350899 bytes, checksum: 78e5538134c2fe53300ad6fda8b8e67b (MD5) Previous issue date: 2006 | en |
| dc.description.tableofcontents | 目錄
致謝………………………………………………………………………I 圖次……………………………………………………………………III 表次 ……………………………………………………………………IV 中文摘要…………………………………………………………………V 英文摘要 ………………………………………………………………VI 壹、緒論…………………………………………………………………1 貳、文獻回顧 一、阿茲海默氏病（Alzheimer’s disease, AD）…………………2 二、類澱粉蛋白(β-amyloid peptide，Aβ) …………………………4 三、微小管（microtubules）…………………………………………7 四、微絲（microfilaments）…………………………………………9 五、海馬回（hippocampus）…………………………………………11 六、二十二碳六烯酸 (Docosahexaenoid acid, DHA) ……………12 參、實驗假說 …………………………………………………………14 肆、材料與方法 一、動物購買與飼養 …………………………………………………16 二、初級海馬回細胞培養 ……………………………………………16 三、MTT viability assay……………………………………………20 四、Cell counting ………………………………………………… 20 五、以氣相層析儀進行脂肪酸分析 …………………………………20 六、以西方點墨法進行蛋白質定量 …………………………………23 七、統計分析 …………………………………………………………28 伍、結果 一、DHA添加對海馬回細胞存活率的影響……………………………29 二、DHA添加抵抗Aβ誘發之神經毒性對海馬回細胞存活率的影響…31 三、DHA添加對海馬回細胞脂肪酸成分的影響 ……………………33 四、DHA添加對海馬回細胞微小管動態蛋白質的影響………………35 五、DHA添加對海馬回細胞微絲蛋白質的影響………………………39 陸、討論 一、實驗條件………………………………………………………… 40 二、DHA添加對海馬回細胞存活率的影響 ………………………… 43 三、DHA添加抵抗Aβ誘發之神經毒性對海馬回細胞存活率的影響…44 四、DHA添加對海馬回細胞脂肪酸成分的影響………………………46 五、DHA添加對細胞骨架動態的影響…………………………………48 柒、結論……………………………………………………………… 49 捌、參考文獻………………………………………………………… 50 | |
| dc.language.iso | zh-TW | |
| dc.title | 探討DHA抵抗類澱粉蛋白誘發之神經毒性以預防阿茲海默氏病之機轉 | zh_TW |
| dc.title | Mechanism of DHA against β-amyloid induced neurotoxicity studied in primary hippocampal cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 94-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 黃青真,呂紹俊,胡孟君 | |
| dc.subject.keyword | 阿茲海默氏病,類澱粉蛋白,微小管,微管,海馬回,二十二碳六烯酸, | zh_TW |
| dc.subject.keyword | β-amyloid,Aβ,microtubule,microfilament,hippocampus,Docosahexaenoid acid,DHA, | en |
| dc.relation.page | 64 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2006-01-27 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 生理學研究所 | zh_TW |
| 顯示於系所單位： | 生理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-95-1.pdf 目前未授權公開取用 | 2.3 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。